TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01062399
Drug: concurrent RAD001 10 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: During radiation: RAD001 10 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
Study: NCT01062399
Drug: concurrent RAD001 2.5 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: During radiation: RAD001 2.5 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
Study: NCT01062399
Drug: concurrent RAD001 5 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: During radiation: RAD001 5 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
Study: NCT01062399
Drug: post-radiation RAD001 10 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-radiation: RAD001 10 mg orally daily on days 1-28 of each cycle, for up to 12 cycles, starting 28 days after the completion of radiation therapy (Cycle = 28 days).
Study: NCT01509586
Drug: Potentially Reduced Exposure Product (PREP): a smokeless, spit-free tobacco product
Approvals — FDA: no, EMA: no, PMDA: no
Description: The PREP Group will be given a sample supply of a PREP product that is already on the market. It is unclear if it is safer than cigarettes, and that is why it is classified as a Potentially Reduced Exposure Product. It provides both nicotine and tobacco in the form of a pouch that can be thrown away after used. Unlike chewing tobacco, there is no need for spitting with this product. There are multiple flavors and participants will have his/her choice of preferred flavor. This group will be asked to sample the product and use it in several ways, but whether a participant uses the product or not is up him/her.
Study: NCT01320579
Drug: Placebo for cis-UCA emulsion cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo for cis-UCA product (emulsion cream base) twice daily, amount of a fingertip per one hand area applied topically as a thin layer on the affected skin area on of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area).
Study: NCT02389413
Drug: PQ912 oral
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02207530
Drug: MEDI4736
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI4736 monotherapy
Study: NCT00536731
Drug: Symbicort Turbuhaler
Normalized name: Symbicort Turbuhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily
Study: NCT00536731
Drug: Symbicort pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily
Study: NCT00474630
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00626795
Drug: TD1414 2% cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID 7 days
Study: NCT00626795
Drug: TD1414 2% cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: TID 7 days
Study: NCT00626795
Drug: Bactroban® (mupirocin) 2% cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID 7 days
Study: NCT00856752
Drug: NRL972
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous administration of 2 mg NRL972 after pre-treatment with 600 mg p.o. rifampicin once daily from the evening of Day D-7 until the evening of Day D-1
Study: NCT00856752
Drug: NRL972
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference test: Single intravenous administration of 2 mg NRL972
Study: NCT00856752
Drug: NRL972
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous administration of 2 mg NRL972 injection after pre-treatment with 100 mg cyclosporine on the evening of Day D-1 and on the morning of Day D01 one hour before administration of NRL972
Study: NCT04385303
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One intra-articular injection of 0 mg lorecivivint in 2 m vehicle
Study: NCT00355589
Drug: Ramipril and hydrochlorothiazide
Normalized name: hydrochlorothiazide / ramipril
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05921916
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule solid microcrystalline cellulose
Study: NCT03267329
Drug: Duowell®
Approvals — FDA: no, EMA: no, PMDA: no
Description: telmisartan 80mg/rosuvastatin 10mg for ASCVD risk=5%\~7.5% or telmisartan 80mg/rosuvastatin 20mg for ASCVD risk≥7.5%
Study: NCT00052429
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02711670
Drug: chlorthalidone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03827577
Drug: Standard medical therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: platinum-based doublet according to local protocols or targeted agents according to EGFR/ALK/ROS-1 mutational status or immunotherapy agents according to PDL1 expression.
Study: NCT04239560
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: During each radiotherapy session, 15 minutes before radiotherapy, the Placebo gel which be free of any chemical used and patients followed up.
Study: NCT01174394
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects of both study arms received orally administered SSRIs for 4 weeks in an open manner. For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.
Study: NCT01671085
Drug: LY3015014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SQ
Study: NCT01671085
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SQ
Study: NCT00984659
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo DISKUS twice a day for 8 weeks
Study: NCT02432677
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil (IV infusion): 0,06mcg.kg.min. The infusion starts 10min before tDCSThe infusion will be stopped in the event of: a decrease in respiratory rate below 7 breaths / min, a peripheral oxygen saturation below 85%, a lower heart rate of 40 beats per minute, a lower mean arterial pressure of 60 mmHg, sedation causing inadequate management switch stimuli tests and occurrence of vomiting.
Study: NCT02432677
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests.
Study: NCT04003636
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to pembrolizumab
Study: NCT01083290
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose of one tablet; 25 mg tablet
Study: NCT01083290
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose of one tablet; 50 mg tablet
Study: NCT01083290
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose of one tablet; 100 mg tablet
Study: NCT03476018
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice a week until 29 days after completion of chemoradiotherapy, then once every 14 days
Study: NCT02183545
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: given as tablet (matching placebo of BI 1060469)
Study: NCT02052960
Drug: CetuGEX™
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/day 0, 930 mg/day 1, followed by 720 mg i.v. weekly administration
Study: NCT02052960
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Cisplatin and 5-Fluorouracil (Carboplatin may substitute Cisplatin following the 1st cycle of therapy in case of toxicity)
Study: NCT01241513
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01615003
Drug: Xuesaitong soft capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuesaitong soft capsule, soft capsule, Ingredients:PNS, Specification:0.33 per bag, once take two pills and twice a day during a month.
Study: NCT01615003
Drug: Xuesaitong soft capsule Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuesaitong soft capsule Placebo, soft capsule, once take two pills and twice a day during a month.
Study: NCT02183298
Drug: BI 1356 BS - intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02183298
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02225067
Drug: Calcium (13C)Carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Visit 1 and Visit 2, 24-hour gastric pH monitoring and C13-CAC breath test containing 200 mg of Calcium (13C)Carbonate
Study: NCT03533257
Drug: AMX0035
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Therapy of PB and TURSO
Study: NCT03533257
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00722592
Drug: pegylated liposomal doxorubicin (PLD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/m\^2 (with dose based on ideal body weight for participants whose measured body weight is greater than their ideal body weight) intravenous infusion on Day 1 of a 4 week cycle. Dose reductions permitted for toxicity.
Study: NCT01312350
Drug: neoadjuvant docetaxel/cisplatin/fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 cycles of neoadjuvant Docetaxel/cisplatin/5-fluorouracil therapy followed by CCRT Neoadjuvant chemotherapy (docetaxel 75mg/m2 D1, cisplatin 75mg/m2 D1, 5-fluoruracil 759mg/m2/day, D1-4, every 3 weeks) CCRT protocol is same with that of control arm.
Study: NCT01312350
Drug: No treatment before definitive CCRT
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: concurrent chemoradiation therapy radiation: 70Gy/35fractions chemotherapy: cisplatin single 100mg/m2/day D1, D22, D43
Study: NCT01022853
Drug: BIBF 1120
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral continuously
Study: NCT00163553
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00675285
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet 5 mg once/day for 4 weeks
Study: NCT00287833
Drug: Bowman-Birk inhibitor concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT04172831
Drug: Placebo SL Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Study: NCT04159519
Drug: Fasenra®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Benralizumab 30 mg/mL, 1 mL fill volume via subcutaneous injection every 4 weeks for first 3 doses (prior to study inclusion), every 8 weeks thereafter.
Study: NCT03246906
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00077584
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets matching bosentan 62.5-mg tablets and bosentan 125-mg tablets
Study: NCT04416776
Drug: Strabismus diagnostic system.
Approvals — FDA: no, EMA: no, PMDA: no
Description: An AI platform based on corneal light-reflection photos to facilitate the diagnosis and angle evaluation of strabismus and to provide advice for surgical planning.
Study: NCT00722540
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 1; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
Study: NCT00722540
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 2; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
Study: NCT00722540
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 3; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
Study: NCT00722540
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 3 repeated; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
Study: NCT00722540
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 4; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
Study: NCT03281226
Drug: RIPE (2m) and RI (4m)
Normalized name: Ri-Mag Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 150mg + isoniazid 75mg + pyrazinamide 400mg + ethambutol 275mg (oral combined fixed dose tablet according to the weight) for 2 months and a continuation with rifampicin 150mg and isoniazid 75mg (oral combined fixed dose tablet according to the weight) for 4 months
Study: NCT03281226
Drug: RIPE+NAC (2m) and RI (4m)
Normalized name: Ri-Mag Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 150 mg + isoniazid 75 mg + pyrazinamide 400 mg + ethambutol 275mg (oral combined fixed dose tablet according to the weight) plus oral N-acetylcysteine (NAC) 1200 mg (600mg twice daily) for 2 months and a continuation with rifampicin 150mg and isoniazid 75mg (oral combined fixed dose tablet according to the weight) for 4 months
Study: NCT03625219
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 tablets for 3 consecutive days; then 6 tablets, 4 tablets, 2 tablets, and 1 tablet daily for 2 consecutive days for each tablet count for a total of 11 days
Study: NCT02004652
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin, 50mg, tablet.
Study: NCT00088010
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, tablet, once a day for 36 months
Study: NCT01901133
Drug: MDV3100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT04341844
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline in total 50 ml volume intravenous administration after induction of anesthesia within one hour.
Study: NCT01544595
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00509873
Drug: placebo eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
Study: NCT01417780
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (0.9% sodium chloride) administered as a single IV infusion
Study: NCT01059604
Drug: Sumatriptan-naproxen combination
Normalized name: naproxen / sumatriptan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan-naproxen combination
Study: NCT01345786
Drug: Commercial NOMAC-E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination commercial tablet orally in the morning on Day 1 for all periods
Study: NCT01345786
Drug: Phase 3 NOMAC-E2 Batch A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination tablet from the Phase 3 clinical trial program (Batch A) orally in the morning on Day 1 for all periods
Study: NCT02096939
Drug: Antihypertensive medication
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02532868
Drug: MK-0457
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00097422
Drug: OPT-80
Normalized name: Glau-Opt
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01666444
Drug: pegylated liposomal doxorubicin (PLD)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01666444
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04150640
Drug: Nal-IRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy drug
Study: NCT01993329
Drug: Placebo to mimic 50 mg tablets
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic gefapixant 50 mg tablets
Study: NCT03242928
Drug: AFQ056
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg and 100 mg tablets taken orally
Study: NCT03242928
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets taken orally BID
Study: NCT03251339
Drug: US-Neulasta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received a single subcutaneous injection of US-Neulasta 6 mg/0.6 mL on Day 1 in morning of treatment period 1 and 2. Period 1 and Period 2 are separated by a washout period of 35 Days.
Study: NCT02461914
Drug: PEX168
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200µg,injected subcutaneously,once a week.
Study: NCT03567291
Drug: TEV-50717
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6, 9, and 12 mg oral tablets
Study: NCT03567291
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT00915967
Drug: Placebo (Saline Solution)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to the saline group will receive an injection (up to 10 mL) of saline solution directly into the wound following watertight fascial closure.
Study: NCT04454996
Drug: Chang 'an II Recipe
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is Chang 'an II Prescription granule, 1 bag each time, 3 times a day, treatment for 4 weeks.
Study: NCT04454996
Drug: The placebo of tong-jiang granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a granule, containing 5% tongyu granule active drug,1 bag each time, 3 times a day, treatment for 4 weeks.
Study: NCT04454996
Drug: The placebo of Chang 'an II Recipe
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a granule containing 5% chang 'an II,1 bag each time, 3 times a day, treatment for 4 weeks.
Study: NCT00923273
Drug: FDG-PET
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET CT will be performed at baseline and after two cycles of treatment.
Study: NCT01097616
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebos to suvorexant 40 mg and 20 mg for participants \<65 years old; matching placebos to suvorexant 30 mg and 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Placebo is a third treatment arm for comparison to the two active (suvorexant) treatment arms during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week DB RO following the TRT/EXT phase, participants in this study arm continue to receive placebo. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
Study: NCT00003386
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01996319
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once a day via Breezhaler® device
Study: NCT00130208
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg gelcap
Study: NCT02405039
Drug: EBI-005
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EBI-005 is an intervention into one of two (2) study arms; 5 mg/mL topical administered 3 times per day
Study: NCT02405039
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or Vehicle control comparator is an intervention into one of two (2) study arms; vehicle topical administered 3 times per day
Study: NCT01505491
Drug: BI695501
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 695501 single s.c injection
Study: NCT03855306
Drug: Glibesyn
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet contains 5 mg Glibenclamide
Study: NCT00658970
Drug: KX2-391
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg (starting dose)rising dose, oral dosing, twice daily, 21 day cycle(s); until progression or unacceptable toxicity develops
Study: NCT00282919
Drug: Azithromycin plus chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dose of 2000 mg Azithromycin plus 600 mg chloroquine base
Study: NCT04742517
Drug: ASP1128
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous
Study: NCT04742517
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous
Study: NCT00153634
Drug: IV amikacin
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-7.5 mg/kg every 8 hrs or previous dose; start at previous recent stable dose then monitor serum levels and adjust dose, if needed, per standard clinical practice at the site
Study: NCT00153634
Drug: PO azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250 mg once daily
Study: NCT04117919
Drug: paper mulberry leaf
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroids+paper mulberry leaf The botanical origin of paper mulberry leaf is Broussonetia papyrifera (L.) Vent.
Study: NCT04516759
Drug: AZD1656
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg film-coated tablets (at daily dose of 100mg BID)
Study: NCT00153634
Drug: IV tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2.5-3.3 mg/kg every 8 hrs or previous dose; start at previous recent stable dose then monitor serum levels and adjust dose, if needed, per standard clinical practice at the site
Study: NCT04199754
Drug: Omnipaque 300mg/mL Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to the contrast enhanced Cone Beam CT, 100mL of Omnipaque will be administered by IV at a rate of 2mL per second, followed by administration of 50mL of 0.9% saline.
Study: NCT04199754
Drug: 0.9% Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ML of 0.9% Saline will be administered immediately after Omnipaque administration
Study: NCT02947139
Drug: Co-administration of DWC20155/DWC20156
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02947139
Drug: DWC20161
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00199186
Drug: methotrexate (intrathecal)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00199186
Drug: AraC (intrathecal)
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02739711
Drug: Glycoprotein IIb/IIIa inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb/IIIa inhibitors intravenous bolus followed by an intravenous infusion for 12/18 h plus medical standard therapy